Literature DB >> 26315525

Personalized Approaches to Gastrointestinal Cancers: Importance of Integrating Genomic Information to Guide Therapy.

Jin He1, Nita Ahuja2.   

Abstract

Cancers are characterized by complex tumor heterogeneity driven by subclones with differential genotypes and phenotypes, which then drives cancer behavior. As genomic strategies become feasible on smaller samples such as biopsies, coupled with decreasing costs of these approaches, clinicians will increasingly use genomic information to drive therapeutic decision making. Early applications of such personalized approaches are discussed. Genetic testing of high-risk family members may identify patients with germline mutations who can have prophylactic surgeries as a cancer prevention strategy. This article discusses examples of successful targeted therapy. Clinical trials need to incorporate genetic testing to stratify patients into different groups.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomarkers; Next-generation sequencing; Targeted therapy; Tumor heterogeneity

Mesh:

Substances:

Year:  2015        PMID: 26315525     DOI: 10.1016/j.suc.2015.05.002

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  2 in total

1.  Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work.

Authors:  Gerard Harty; James Jarrett; Mireia Jofre-Bonet
Journal:  Appl Health Econ Health Policy       Date:  2018-08       Impact factor: 2.561

2.  Integrating transcriptomics and bulk time course data into a mathematical framework to describe and predict therapeutic resistance in cancer.

Authors:  Kaitlyn E Johnson; Grant R Howard; Daylin Morgan; Eric A Brenner; Andrea L Gardner; Russell E Durrett; William Mo; Aziz Al'Khafaji; Eduardo D Sontag; Angela M Jarrett; Thomas E Yankeelov; Amy Brock
Journal:  Phys Biol       Date:  2020-11-20       Impact factor: 2.583

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.